The Power of Cutting-Edge Technology

Agilent is at the forefront of technology innovation to unlock the promise of precision medicine.

The Future of Targeted Treatment

Agilent is a leading partner to drive clinical utility into proven pathways while helping to enable the next generation of predictive biomarkers.

The Need for Expertise

At Agilent DX, dedicated experts collaborate to combine experience with innovation, enabling the full potential of biomarker-driven landmark therapies.

Technologies in bold represent current Agilent capabilities

Note:
Technologies in bold may not be approved for diagnostic use.

References:
5. Porta, C.; Paglino, C.; Mosca, A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front. Oncol. 2014, 4, 64.

This information is subject to change without notice. © Agilent Technologies, Inc. 2019 Published in the USA, September 3, 2019.
Agilent has leveraged robust and versatile technology and a customized co-development process to enable the development of the first PD-L1 companion and complementary diagnostic assays.

**The Experience of a Trusted Navigator**

Agilent has leveraged robust and versatile technology and a customized co-development process to enable the development of the first PD-L1 companion and complementary diagnostic assays.

**References:**

**PD-L1 IHC 28-8 pharmDx**

**HER2 IQFISH pharmDx**

**HER2 CISH pharmDx**

**c-Kit pharmDx**

**PD-L1 IHC 22C3 pharmDx**

**PD-L1 IHC 28-8 pharmDx**

**HER2 HercepTest**

**EGFR pharmDx**

**ER/PR pharmDx**

**Precision Medicine, Powered by Partnership**

Discover how Agilent companion diagnostics (CDx) can help enable your targeted therapy programs for patients.

**The Expertise to Guide and Deliver**

The combination of experienced people, optimized processes, and best-in-class technology make Agilent the ideal partner to drive a co-development program.

**People**

Seasoned professionals at all stages of co-development, from discovery to commercialization.

Dedicated CDx division ensuring intense customer focus backed by Agilent's broad expertise across cross-divisional resources.

**Process**

Adaptive program management boosts versatility and customization to best meet partner needs.

Center of Excellence enables integrated end-to-end alignment across the entire product development process.

Agile and rigorous design control to support global registration.

**Technology**

A comprehensive portfolio of legacy and emerging technologies from a single partner.

Access to Agilent's full range of technology, platforms, and analytics to power decisions based on biology and data.

**Get in touch to explore collaborative partnerships with Agilent that advance CDx-enabled therapy.**

Gulzar Sandhu
Head of Business Development, Companion Diagnostics
CDxpartnerships@agilent.com | agilent.com/en/CDx

**Tested with PD-L1 IHC 22C3 pharmDx, treated with pembrolizumab**

**Tested with PD-L1 IHC 28-8 pharmDx, treated with nivolumab**

**Tested with HercepTest, treated with trastuzumab**